Gero

Gero is a preclinical stage company based in Palo Alto, California. The company employs 81 individuals and generated $5.9 million in revenue. Gero focuses on utilizing artificial intelligence (AI) to advance drug discovery. Gero leverages AI algorithms to analyze real-world human data, constructing clinically relevant disease phenotypes. This analysis allows them to identify diseases sharing similar biological mechanisms. Subsequently, the company conducts whole-exome sequencing (WES)-enabled genetic studies on these phenotypes to uncover novel therapeutic targets applicable to multiple disease areas simultaneously. Gero's unique approach aims to accelerate the drug discovery process by identifying shared biological pathways across various age-related diseases. Their research is published in peer-reviewed journals, highlighting their commitment to scientific rigor and transparency. For more information about Gero and their research, visit their website at gero.ai. You can also explore their published research through the link provided on their website: gero.ai/publications.